The pharmacokinetic parameters of intravenous ciprofloxacin were examined in five adult male patients on three separate occasions of open heart surgery: the 24 h before cardiopulmonary bypass (CPB) surgery, (PRE), during surgery (SURG), and 48 to 72 h after surgery (POST). Serial blood (n = 16), urine, and SURG tissue samples were collected after intravenous administration of a single 300-mg dose of ciprofloxacin during each study period. All samples were assayed for ciprofloxacin by a specific high-performance liquid chromatographic method. Serum ciprofloxacin concentrations remained constant or continued to decline during the course of CPB surgery. A significant (P < 0.05) decrease in total body clearance was observed during the SURG and POST phases (298 and 306 ml/min/1.73 m2, respectively) compared with that during the PRE phase (364 ml/min/1.73 m2). Renal clearances and elimination half-lives were similar during all three study phases. A nonsignificant decline occurred in the apparent volume of distribution, from mean values of 2.1 and 2.0 liters/kg during the PRE and POST phases, respectively, to 1.7 liters/kg during the SURG phase. The mediastinal fat tissue ciprofloxacin concentrations ranged from 0.45 to 2.89 ,ug/g. Overall, little significant difference was noted in the disposition of intravenous ciprofloxacin during CPB surgery compared with that before and after surgery.
Infectious complications following open heart surgery have been associated with significant morbidity and mortality (20, 21, 24) . These infectious complications include wound infection and valvular endocarditis. Pre-and perioperative antimicrobial prophylaxis are used routinely to reduce the risk of these infectious complications (5, 8) . It has been established that prophylactically administered antibiotics can decrease the incidence of infections following procedures that use cardiopulmonary bypass (CPB) if adequate concentrations are present at the initiation of surgery and are maintained throughout the surgical procedure (9, 25) .
Staphylococcus aureus and Staphylococcus epidermidis are the most common pathogens associated with cardiothoracic procedures (17) . A cephalosporin (narrow or expanded spectrum) or vancomycin is the agent of choice for antimicrobial prophylaxis against these pathogens. Gram-negative bacteria may also contribute to the infectious process of cardiothoracic surgery (17) . Similar to the role of aminoglycosides, intravenous ciprofloxacin could be added for prophylaxis against the gram-negative pathogens and may have some prophylactic effect against staphylococci. going open heart operations which require CPB (3, 10) . Decreases in cardiac output, organ perfusion, renal function, and intrinsic metabolic activity have been documented in association with CPB. These changes in renal function and organ perfusion may in turn alter the processes of drug absorption, distribution, metabolism, and excretion. In addition, hypothermia and dilutional factors associated with CPB may also influence drug disposition, protein binding, and enzyme-mediated elimination pathways. Previous studies have documented the fact that changes in drug disposition indeed do occur in association with CPB. Furthermore, these physiologic changes and their resultant effects on the pharmacokinetics of drugs do not remain constant throughout the time on CPB.
Currently, little information is available regarding ciprofloxacin penetration into tissue when the drug is administered intravenously and the systemic disposition of ciprofloxacin during CPB surgery. The objective of the present study was to investigate the effects of CPB surgery on the pharmacokinetics of intravenous ciprofloxacin.
MATERIALS AND METHODS
Patients. Adult patients scheduled to undergo elective open heart surgery requiring CPB (either single valve replacement or coronary artery bypass grafting) were eligible for entry into the study after informed written consent was obtained. To reduce the effect of intrapatient changes and variability, each subject served as his own control. All patients were studied on three separate occasions: (i) 24 Sample collection. Venous blood samples were collected during the PRE phase of the study, and arterial blood was sampled during the SURG and POST phases. Three to 5 ml of blood was collected as described above at the following times: preinfusion, midinfusion (30 min after the start of the infusion), end of infusion, and 0.083, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 12 h after the end of the infusion in each of the three study treatments. The exact time that blood was drawn during the SURG phase was modified on several occasions to correspond to the timing of tissue sample collection and to correspond to four events of the CPB surgery: (i) pre-bypass, (ii) during bypass with crossclamped aorta, (iii) during bypass with unclamped aorta, and (iv) post-bypass. POST phase sample collection times were also adjusted to correspond to the sampling strategy during the SURG phase to maintain consistency for comparison. Blood samples were collected in nonheparinized tubes and were centrifuged within 3 h of collection, and the serum was harvested and stored. All serum, urine, and tissues samples were stored at -70°C until assayed.
Twenty-four-hour urine collections were done at the intervals corresponding to the four phases of surgery on each of the 3 treatment days. Urine was collected at the intervals 0 to 2, 2 to 4, 4 to 6, and 6 to 24 h. After collection of each urine sample, the volume was measured and recorded and the sample was returned to its original container. After shaking, two 25-ml aliquots were removed and stored until analysis.
Samples of mediastinal fat tissue were collected during the SURG phase of the study. At the time of tissue harvest, corresponding blood samples were collected for comparative analysis. The weights of all tissue samples were recorded. The tissue samples were homogenized with 2 ml of 0.1 N phosphoric acid per gram of tissue by using a handheld mechanical tissue homogenizer. The homogenizer was submerged in an ice bath to prevent heat degradation of the tissue. After homogenization, the tube containing the sample was capped and stored in an upright position. Tissue ciprofloxacin concentrations were determined by a high-performance liquid chromatographic (HPLC) method (13) .
Assay. All samples were assayed for ciprofloxacin by a specific HPLC method (13) . The standard curve ranged from 0.01 to 2.5 ,ug/ml. The intra-and interday coefficients of variation for serum assays ranged from 7.5 to 9% at a ciprofloxacin concentration of 0.01 ,ug/ml and from 2 to 4% at a concentration of 2.5 p,g/ml. All samples with concentrations in serum of greater than 2.5 ,ug/ml were reassayed by using a 1:1 dilution with 0.1 N phosphoric acid. Urine samples were assayed by using a polystyrene-divinyl column (4.6 mm by 15 cm; SU; Polymer Laboratories, Amherst, Mass.) with UV detection. The standard curves ranged from 0.1 to 10 ±g/ml. Any urine samples containing ciprofloxacin at concentrations exceeding this range were reassayed after being diluted 1:1 with 0.1 N phosphoric acid. The intra-and interday coefficients of variation for the urine assay ranged from 6 to 8% at a concentration of 0.1 ,ug/ml and 2 to 4% at a concentration of 10 ,g/ml. No cross-reactivity between therapeutic agents used during CPB surgery at our institution and the ciprofloxacin assay was demonstrated prior to the initiation of the present study (18a).
Pharmacokinetic analysis. During all three study phases, the area under the curve (AUC) was calculated by the linear trapezoidal rule to the last measured ciprofloxacin concentration in serum. The residual area was calculated by dividing the last serum drug concentration datum point by the terminal elimination rate constant (1). For patients studied during the SURG and POST phases, the area contribution from previous doses was calculated by dividing the predose concentration in serum by ,B. The AUC for that dose was then corrected by subtracting this area.
During the PRE and POST phases, 1 was calculated by nonlinear least-squares regression fit of the serum ciprofloxacin concentration-time data by PCNONLIN (Statistical Consultants, Inc., Lexington, Ky.). Selection of the appropriate pharmacokinetic model was determined by a modeldiscriminating F ratio test and the difference between measured and computer-fitted ciprofloxacin concentrations (2) . During the SURG phase, 13 was obtained from a nonlinear least-squares regression of the serum ciprofloxacin concen- Statistical analysis. Overall differences in pharmacokinetic parameters for ciprofloxacin across the three study phases were evaluated by repeated-measures analysis of variance. When significant differences were found, individual differences between the PRE and SURG phases and the PRE and POST phases were evaluated by a Tukey's test. Significance was determined at the P < 0.05 level.
RESULTS
A total of five male patients ranging in age from 53 to 74 years and undergoing three-vessel coronary artery bypass were enrolled in the trial. While patients undergoing valvular procedures were eligible, no such patients were available for enrollment at the time of the study. Table 1 lists complete demographic information on the patient population.
The mean + SD time on CPB surgery and total aortic cross-clamp time were 153 ± 59 and 89.6 ± 19 min, respectively. The average time from the end of the ciprofloxacin infusion until CPB was initiated was 69 min ( Table 2 ). The total duration of anesthesia ranged from 4.4 to 8.25 h.
Superimposed representative concentration-time curves for all three phases of the study for two patients are presented in Fig. 1 and 2 . Selected mean ± SD serum ciprofloxacin concentrations during the SURG phase of the study are presented in Table 2 . A comparison of mean serum ciprofloxacin concentration pre-bypass and immediately at the start of CPB showed a mean decrease of 0.93 ,ug/ml. Serum ciprofloxacin concentrations declined during CPB, and no rebound of concentrations was noted in any of the five patients.
Pharmacokinetic comparisons from all three study phases are listed in Table 3 . In comparison with the PRE phase values, the CL of ciprofloxacin significantly (P < 0.05) decreased during CPB surgery and remained decreased for 48 to 72 h following surgery. In contrast, CLR of ciprofloxacin increased slightly and remained above PRE phase levels at 48 to 72 h after surgery. The apparent volume of distribution moderately decreased during the SURG phase, with a return to near PRE phase values by 48 to 72 h after surgery.
The tl/2,, increased marginally and remained increased during the POST phase. Overall, changes in pharmacokinetic parameters of ciprofloxacin appear to be marginally affected by CPB surgery.
Ciprofloxacin concentrations in mediastinal fat tissue during the SURG phase are listed in Table 4 . Concentrations in tissue ranged from 2.89 ,ug/g at 0.23 h following administration to 0.45 ,ug/g at 9.6 h following administration. The highest concentrations in tissue occurred from 15 to 75 min after the end of the ciprofloxacin infusion. 
DISCUSSION
The effects of CPB on the pharmacokinetics of numerous drugs have been evaluated since the late 1970s (3, 10) . Among currently available antimicrobial agents, cephalosporins have undergone the most extensive evaluations; however, the dispositions of other antibiotics including gentamicin, netilmicin, and vancomycin have been studied (12, 17) . To date, investigations with ciprofloxacin have dealt primarily with the determination of tissue penetration and not the effect of CPB on ciprofloxacin disposition (18, 22) .
No dramatic initial drop in the concentration of ciprofloxacin was noted after the initiation of CPB. Our patient 10 population demonstrated a mean decline in serum ciprofloxacin concentrations of 38.3% when comparing the concentrations in serum obtained immediately prior to the initiation of CPB and concentrations immediately after CPB was started. However, as evidenced by the superimposed overlapping disposition curves in patients during the PRE, SURG, and POST phases of the protocol (Fig. 2) , this decline could be explained by the normal distribution phases of ciprofloxacin disposition (7) . A notable variance from the PRE phase of the protocol was a modest decline in mean V., from 2.1 ± 0.7 to 1.7 ± 0.2 liters/kg ( Table 3 ). The most likely sources of this variance in V.. are changes in tissue perfusion and penetration and/or hemodilution (1, 12, 19) . Ciprofloxacin distributes widely into tissues, including extensive penetration into bronchopulmonary and peripheral tissues. Once CPB is initiated, perfusion into tissues in these areas may be diminished. Hemodilution could also account for this finding, since 2 liters of colloid solution are administered at the onset of CPB. It is less likely that protein binding changes could have accounted for the decrease in V,, during the SURG phase since ciprofloxacin exhibits a relatively low degree of protein binding (30 to 35%) (7, 11) .
Klamerus and coworkers (12) reported a rebound in netilmicin concentrations during CPB surgery as well as a rebound of vancomycin concentrations when the aorta was unclamped. Our data did not demonstrate any rebound effect during CPB surgery. However, this effect appears to be drug dependent, because other investigators also did not observe a rebound in the concentrations of cefuroxime or gentamicin in serum (17) .
CL decreased during the SURG and POST phases compared with the CL during the PRE phase (Table 3) . While the decrease in CL is statistically significant (P < 0.05), the average decreases in CL during the SURG and POST phases were only 18.8% (range, 15 to 25%) and 15.3% (range, 1 to 30%), respectively. The decreases in CL probably have (6, 23) . Recently published data obtained with intravenous doses of 300 and 400 mg infused over 60 min have become available; however, again, these data were derived in young (ages, 21 to 35 years), healthy males (15) . The pharmacokinetic parameters obtained during the PRE phase were consistent, but with less interpatient variability than those reported in normal volunteers (15) . This is most likely due to the relatively small and homogeneous population that we studied; nonetheless, it provides substantive comparative baseline data. The apparent volume of distribution for our patient population was 159.2 liters, whereas Lettieri et al. (15) reported an apparent volume of distribution of 178 liters. However, our values for CL and CLR during the PRE phase were significantly lower than those reported in young subjects (CL, 394 + 81 versus 603 ± 127 liters, respectively; CLR, 166 ± 61 versus 388 ± 42 liters, respectively). Our lower values are most likely a reflection of an age-related decline in renal function, since both the CL and CLR of ciprofloxacin are directly related to creatinine clearance and our patients were older (mean age, 63 years), with a mean creatinine clearance of 61.8 ml/min/1.73 m2 (Table 1) (6) .
Penetration into mediastinal fat tissue was consistent with those presented in other reports, and ciprofloxacin demonstrated adequate tissue penetration (14, 18, 22, 23) . Concentrations of ciprofloxacin in mediastinal fat tissue remained above the MIC for 90% of most pathogenic organisms associated with CPB surgery up to 4.5 h after intravenous administrations of ciprofloxacin (Table 4) . Overall, CPB surgery did not appear to hamper penetration into mediastinal fat tissue.
In summary, our observations demonstrate that CPB surgery has minimal influence on the disposition of intravenous ciprofloxacin. Further comparative efficacy data will be needed prior to recommending this agent as a prophylactic medication in patients undergoing coronary artery bypass grafting or cardiac valve replacement procedures requiring CPB.
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